Atricure Inc (NASDAQ: ATRC) on Friday, soared 3.41% from the previous trading day, before settling in for the closing price of $39.59. Within the past 52 weeks, ATRC’s price has moved between $18.94 and $43.11.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 20.90% over the last five years. The company achieved an average annual earnings per share of 27.63%. With a float of $47.16 million, this company’s outstanding shares have now reached $48.87 million.
The firm has a total of 1300 workers. Let’s measure their productivity. In terms of profitability, gross margin is 74.29%, operating margin of -7.63%, and the pretax margin is -8.44%.
Atricure Inc (ATRC) Insider Activity
Observing investor behavior towards Medical Instruments & Supplies industry stocks is more important than anything else. The insider ownership of Atricure Inc is 3.26%, while institutional ownership is 96.37%. The most recent insider transaction that took place on Aug 15 ’24, was worth 84,245. In this transaction Director of this company sold 3,500 shares at a rate of $24.07, taking the stock ownership to the 8,970 shares. Before that another transaction happened on Aug 15 ’24, when Company’s Director proposed sale 3,500 for $24.07, making the entire transaction worth $84,245.
Atricure Inc (ATRC) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.15 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 27.63% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 53.58% during the next five years compared to -0.33% drop over the previous five years of trading.
Atricure Inc (NASDAQ: ATRC) Trading Performance Indicators
Atricure Inc (ATRC) is currently performing well based on its current performance indicators. A quick ratio of 2.62 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.29.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.95, a number that is poised to hit -0.22 in the next quarter and is forecasted to reach -0.38 in one year’s time.
Technical Analysis of Atricure Inc (ATRC)
Analysing the last 5-days average volume posted by the [Atricure Inc, ATRC], we can find that recorded value of 0.68 million was better than the volume posted last year of 0.61 million. As of the previous 9 days, the stock’s Stochastic %D was 62.10%. Additionally, its Average True Range was 1.81.
During the past 100 days, Atricure Inc’s (ATRC) raw stochastic average was set at 87.63%, which indicates a significant increase from 56.69% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 44.44% in the past 14 days, which was lower than the 48.97% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $35.91, while its 200-day Moving Average is $28.61. Now, the first resistance to watch is $41.62. This is followed by the second major resistance level at $42.30. The third major resistance level sits at $43.48. If the price goes on to break the first support level at $39.77, it is likely to go to the next support level at $38.59. Should the price break the second support level, the third support level stands at $37.91.
Atricure Inc (NASDAQ: ATRC) Key Stats
Market capitalization of the company is 2.00 billion based on 48,753K outstanding shares. Right now, sales total 399,250 K and income totals -30,440 K. The company made 115,910 K in profit during its latest quarter, and -7,850 K in sales during its previous quarter.
